Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Clinical trial NCT00295932 · COMPLETED
Trial details
- NCT number
- NCT00295932
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-12-13
- Primary completion
- 2018-03-11
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.